IntelGenx Corp. signed a definitive agreement with Chemo Group for the co-development and commercialization of a generic tablet in the area of CNS (central nervous system) on a worldwide basis. This definitive agreement signed December 30, 2016. Under the agreement, IntelGenx is entitled to an upfront payment development costs of the product and future milestone payments. Chemo and IntelGenx will also share the profits of Commercialization.